- Feb 27 – Preliminary results from Part 2 of ACE-083 Phase 2 CMT trial expected by the end of 2019 News
- Feb 12 – Neurogene nets $68.5M to advance gene therapies for rare neurological diseases including CMT4J News
- Feb 08 – A network biology approach to unraveling inherited axonopathies including CMT2 Research
- Feb 07 – Neurogene Announces Presentation of Preclinical Data for Gene Therapies to Treat AGU and CMT4J, Two Rare and Devastating Neurodegenerative Disorders News
- Feb 05 – Altered interplay between endoplasmic reticulum and mitochondria in Charcot–Marie–Tooth type 2A neuropathy Research
- Feb 04 – Pharnext Announces FDA Fast Track Designation for PLEODRUG(TM) PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A News
CMT Treatment Report
www.CMTTreatmentReport.com
